Coherus Oncology, Inc. Selling, General and Administrative Expense
Coherus Oncology, Inc. (CHRS) reported Selling, General and Administrative Expense of $20.95 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:SellingGeneralAndAdministrativeExpense · last filed 2026-08-05
- Coherus Oncology, Inc. selling, general and administrative expense for the quarter ending 2026-06-30 was $20.95M, a 19.53% decline year-over-year.
- Coherus Oncology, Inc. selling, general and administrative expense for the quarter ending 2026-03-31 was $23.10M, a 11.22% decline year-over-year.
- Coherus Oncology, Inc. selling, general and administrative expense for the quarter ending 2025-12-31 was $23.61M, a 20.26% decline year-over-year.
- Coherus Oncology, Inc. selling, general and administrative expense for the quarter ending 2025-09-30 was $24.93M, a 11.36% decline year-over-year.
- Coherus Oncology, Inc. selling, general and administrative expense for fiscal 2025 was $100.60M, a 19.83% decline from fiscal 2024.
- Coherus Oncology, Inc. selling, general and administrative expense for fiscal 2024 was $125.48M.
- Coherus Oncology, Inc. selling, general and administrative expense for fiscal 2022 was $198.48M, a 16.95% increase from fiscal 2021.
- Coherus Oncology, Inc. selling, general and administrative expense for fiscal 2021 was $169.71M, a 22.03% increase from fiscal 2020.
| Period end | Selling, General and Administrative Expense 3 month | Selling, General and Administrative Expense 3 month as first filed | Selling, General and Administrative Expense 6 month | Selling, General and Administrative Expense 6 month as first filed | Selling, General and Administrative Expense 9 month | Selling, General and Administrative Expense 9 month as first filed | Selling, General and Administrative Expense 12 month | Selling, General and Administrative Expense 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $20.95M 10-Q · filed 2026-08-05 | $44.06M 10-Q · filed 2026-08-05 | $67.67M derived: sum of 3 quarters · filed 2026-08-05 | $92.60M derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2026-03-31 | $23.10M 10-Q · filed 2026-05-11 | $46.71M derived: sum of 2 quarters · filed 2026-05-11 | $71.64M derived: sum of 3 quarters · filed 2026-05-11 | $97.68M derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2025-12-31 | $23.61M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | $48.54M derived: sum of 2 quarters · filed 2026-03-09 | $74.58M derived: sum of 3 quarters · filed 2026-08-05 | $100.60M 10-K · filed 2026-03-09 | ||||
| 2025-09-30 | $24.93M 10-Q · filed 2025-11-06 | $50.97M derived: sum of 2 quarters · filed 2026-08-05 | $77.00M 10-Q · filed 2025-11-06 | $106.60M derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2025-06-30 | $26.04M 10-Q · filed 2026-08-05 | $52.06M 10-Q · filed 2026-08-05 | $81.67M derived: sum of 3 quarters · filed 2026-08-05 | $109.80M derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2025-03-31 | $26.02M 10-Q · filed 2026-05-11 | $55.63M derived: sum of 2 quarters · filed 2026-05-11 | $83.76M derived: sum of 3 quarters · filed 2026-05-11 | $111.28M derived: sum of 4 quarters · filed 2026-05-11 | ||||
| 2024-12-31 | $29.61M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | $57.73M derived: sum of 2 quarters · filed 2026-03-09 | $85.25M derived: sum of 3 quarters · filed 2026-03-09 | $125.48M 10-K · filed 2026-03-09 | $167.74M 10-K · filed 2025-03-17 | |||
| 2024-09-30 | $28.13M 10-Q · filed 2025-11-06 | $34.74M 10-Q · filed 2024-11-06 | $55.64M derived: sum of 2 quarters · filed 2025-11-06 | $95.87M 10-Q · filed 2025-11-06 | $126.44M 10-Q · filed 2024-11-06 | $73.81M derived: sum of 4 quarters · filed 2025-11-13 | ||
| 2024-06-30 | $27.52M 10-Q · filed 2025-08-07 | $35.16M 10-Q · filed 2024-08-08 | $67.75M 10-Q · filed 2025-08-07 | $91.70M 10-Q · filed 2024-08-08 | $45.68M derived: sum of 3 quarters · filed 2025-11-13 | $93.91M derived: sum of 4 quarters · filed 2025-11-13 | ||
| 2024-03-31 | $40.23M 10-Q · filed 2025-05-12 | $56.53M 10-Q · filed 2024-05-09 | $18.17M derived: sum of 2 quarters · filed 2025-11-13 | $66.39M derived: sum of 3 quarters · filed 2025-11-13 | $111.54M derived: sum of 4 quarters · filed 2025-11-13 | |||
| 2023-12-31 | -$22.06M derived: 8-K 12 month − 10-Q 9 month · filed 2025-11-13 | $26.16M derived: sum of 2 quarters · filed 2025-11-13 | $71.31M derived: sum of 3 quarters · filed 2025-11-13 | $120.46M 8-K · filed 2025-11-13 | $192.01M 10-K · filed 2024-03-15 | |||
| 2023-09-30 | $48.22M 10-Q · filed 2024-11-06 | $93.37M derived: sum of 2 quarters · filed 2024-11-06 | $142.52M 10-Q · filed 2024-11-06 | $196.14M derived: sum of 4 quarters · filed 2025-03-17 | ||||
| 2023-06-30 | $45.14M 10-Q · filed 2024-08-08 | $94.30M 10-Q · filed 2024-08-08 | $147.92M derived: sum of 3 quarters · filed 2025-03-17 | $192.75M derived: sum of 4 quarters · filed 2025-03-17 | ||||
| 2023-03-31 | $49.15M 10-Q · filed 2024-05-09 | $102.77M derived: sum of 2 quarters · filed 2025-03-17 | $147.60M derived: sum of 3 quarters · filed 2025-03-17 | $198.88M derived: sum of 4 quarters · filed 2025-03-17 | ||||
| 2022-12-31 | $53.62M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-17 | $98.45M derived: sum of 2 quarters · filed 2025-03-17 | $149.73M derived: sum of 3 quarters · filed 2025-03-17 | $198.48M 10-K · filed 2025-03-17 | ||||
| 2022-09-30 | $44.83M 10-Q · filed 2023-11-06 | $96.11M derived: sum of 2 quarters · filed 2023-11-06 | $144.86M 10-Q · filed 2023-11-06 | $194.91M derived: sum of 4 quarters · filed 2024-03-15 | ||||
| 2022-06-30 | $51.28M 10-Q · filed 2023-08-02 | $100.03M 10-Q · filed 2023-08-02 | $150.08M derived: sum of 3 quarters · filed 2024-03-15 | $190.01M derived: sum of 4 quarters · filed 2024-03-15 | ||||
| 2022-03-31 | $48.75M 10-Q · filed 2023-05-08 | $98.81M derived: sum of 2 quarters · filed 2024-03-15 | $138.73M derived: sum of 3 quarters · filed 2024-03-15 | $179.07M derived: sum of 4 quarters · filed 2024-03-15 | ||||
| 2021-12-31 | $50.05M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-15 | $89.98M derived: sum of 2 quarters · filed 2024-03-15 | $130.32M derived: sum of 3 quarters · filed 2024-03-15 | $169.71M 10-K · filed 2024-03-15 | ||||
| 2021-09-30 | $39.92M 10-Q · filed 2022-11-08 | $80.27M derived: sum of 2 quarters · filed 2022-11-08 | $119.66M 10-Q · filed 2022-11-08 | $157.35M derived: sum of 4 quarters · filed 2023-03-06 | ||||
| 2021-06-30 | $40.34M 10-Q · filed 2022-08-04 | $79.74M 10-Q · filed 2022-08-04 | $117.43M derived: sum of 3 quarters · filed 2023-03-06 | $149.41M derived: sum of 4 quarters · filed 2023-03-06 | ||||
| 2021-03-31 | $39.39M 10-Q · filed 2022-05-05 | $77.08M derived: sum of 2 quarters · filed 2023-03-06 | $109.07M derived: sum of 3 quarters · filed 2023-03-06 | $143.12M derived: sum of 4 quarters · filed 2023-03-06 | ||||
| 2020-12-31 | $37.69M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-06 | $69.68M derived: sum of 2 quarters · filed 2023-03-06 | $103.73M derived: sum of 3 quarters · filed 2023-03-06 | $139.08M 10-K · filed 2023-03-06 | ||||
| 2020-09-30 | $31.98M 10-Q · filed 2021-11-08 | $66.04M derived: sum of 2 quarters · filed 2021-11-08 | $101.39M 10-Q · filed 2021-11-08 | $137.46M derived: sum of 4 quarters · filed 2022-02-23 | ||||
| 2020-06-30 | $34.05M 10-Q · filed 2021-08-05 | $69.40M 10-Q · filed 2021-08-05 | $105.47M derived: sum of 3 quarters · filed 2022-02-23 | $137.30M derived: sum of 4 quarters · filed 2022-02-23 | ||||
| 2020-03-31 | $35.35M 10-Q · filed 2021-05-06 | $71.42M derived: sum of 2 quarters · filed 2022-02-23 | $103.25M derived: sum of 3 quarters · filed 2022-02-23 | $139.70M derived: sum of 4 quarters · filed 2022-02-23 | ||||
| 2019-12-31 | $36.07M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-23 | $67.90M derived: sum of 2 quarters · filed 2022-02-23 | $104.35M derived: sum of 3 quarters · filed 2022-02-23 | $137.04M 10-K · filed 2022-02-23 | ||||
| 2019-09-30 | $31.83M 10-Q · filed 2020-11-05 | $68.28M derived: sum of 2 quarters · filed 2020-11-05 | $100.97M 10-Q · filed 2020-11-05 | $134.81M derived: sum of 4 quarters · filed 2021-02-25 | ||||
| 2019-06-30 | $36.46M 10-Q · filed 2020-08-06 | $69.14M 10-Q · filed 2020-08-06 | $102.98M derived: sum of 3 quarters · filed 2021-02-25 | $128.35M derived: sum of 4 quarters · filed 2021-02-25 | ||||
| 2019-03-31 | $32.68M 10-Q · filed 2020-05-07 | $66.52M derived: sum of 2 quarters · filed 2021-02-25 | $91.89M derived: sum of 3 quarters · filed 2021-02-25 | $110.28M derived: sum of 4 quarters · filed 2021-02-25 | ||||
| 2018-12-31 | $33.84M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25 | $59.21M derived: sum of 2 quarters · filed 2021-02-25 | $77.60M derived: sum of 3 quarters · filed 2021-02-25 | $94.18M 10-K · filed 2021-02-25 | ||||
| 2018-09-30 | $25.37M 10-Q · filed 2019-11-08 | $43.76M derived: sum of 2 quarters · filed 2019-11-08 | $60.34M 10-Q · filed 2019-11-08 | |||||
| 2018-06-30 | $18.39M 10-Q · filed 2019-08-05 | $34.97M 10-Q · filed 2019-08-05 | ||||||
| 2018-03-31 | $16.58M 10-Q · filed 2019-05-09 | |||||||
| 2017-12-31 | $71.30M 10-K · filed 2020-02-27 | |||||||
| 2016-12-31 | $51.60M 10-K · filed 2019-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Alpha Cognition Inc. (ACOG) | $0.185B | -6.77 | |
| PRECISION BIOSCIENCES INC (DTIL) | United States | $0.175B | -3.95 |
| Voyager Therapeutics, Inc. (VYGR) | United States | $0.173B | -1.99 |
| Protara Therapeutics, Inc. (TARA) | United States | $0.198B | -3.22 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Compass Therapeutics, Inc. (CMPX) | United States | $0.204B | -5.35 |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Alector, Inc. (ALEC) | United States | $0.213B | -1.90 |
| ANAVEX LIFE SCIENCES CORP. (AVXL) | United States | $0.218B | -18.37 |